Dihydropyrimidine Dehydrogenase Genotype Mayo Clinic Laboratories Mayo Clinic
United States | 4 | 1 | - T Targeted variant analysis
|
DPYD Full Gene Sequencing Mayo Clinic Laboratories Mayo Clinic
United States | 4 | 1 | - C Sequence analysis of the entire coding region
|
CentoMetabolic MOx Centogene AG - the Rare Disease Company
Germany | 195 | 221 | - A Analyte
- D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
|
CentoScreen Centogene AG - the Rare Disease Company
Germany | 316 | 314 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
DPYD - NGS including CNV analysis Centogene AG - the Rare Disease Company
Germany | 1 | 1 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
|
Carrier Screening Guidelines-Based Panel Ambry Genetics
United States | 199 | 165 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
|
CentoNeuro Panel Centogene AG - the Rare Disease Company
Germany | 1886 | 1858 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
|
Epilepsy Panel Centogene AG - the Rare Disease Company
Germany | 734 | 744 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Intellectual Disability Panel Centogene AG - the Rare Disease Company
Germany | 777 | 770 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
CentoIEM Panel Centogene AG - the Rare Disease Company
Germany | 669 | 688 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
|
CentoICU Panel Centogene AG - the Rare Disease Company
Germany | 829 | 848 | - C Sequence analysis of the entire coding region
|
Lysosomal Storage Disorders Panel PreventionGenetics
United States | 242 | 146 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Dihydropyrimidine dehydrogenase deficiency, 274270, Autosomal recessive (Dihydropyrimidine dehydrogenase deficiency) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey | 1 | 1 | - D Deletion/duplication analysis
|
Dihydropyrimidine dehydrogenase deficiency, 274270, Autosomal recessive (Dihydropyrimidine dehydrogenase deficiency) (DPYD gene) (Sequence Analysis-All Coding Exons) (Prenatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey | 1 | 1 | - C Sequence analysis of the entire coding region
|
Dihydropyrimidine dehydrogenase deficiency, 274270, Autosomal recessive (Dihydropyrimidine dehydrogenase deficiency) (DPYD gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey | 1 | 1 | - C Sequence analysis of the entire coding region
|
Dihydropyrimidine dehydrogenase deficiency, 274270, Autosomal recessive (Dihydropyrimidine dehydrogenase deficiency) (Prenatal) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey | 1 | 1 | - D Deletion/duplication analysis
|
5-fluorouracil toxicity, 274270, Autosomal recessive (Dihydropyrimidine dehydrogenase deficiency) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey | 1 | 1 | - D Deletion/duplication analysis
|
5 fluorouracil toxicity (DPD gene - Allel 2A-IVS14+1G-A and *3,*4,*5A,*7,*8,*9,*10,*12,*13, M166V, R886H, D949V allels) (SnapShot analysis) (DPYD gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey | 1 | 1 | - C Sequence analysis of the entire coding region
|
5-fluorouracil toxicity, 274270, Autosomal recessive (Dihydropyrimidine dehydrogenase deficiency) (DPYD gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey | 1 | 1 | - C Sequence analysis of the entire coding region
|
Pharmacogenomics Test Panel IU Genetic Testing Laboratories Indiana University School of Medicine
United States | 8 | 13 | - T Targeted variant analysis
|
